Lung Cancer Clinical Trials in Shanghai, Shanghai Municipality
95 recruitingShanghai, Shanghai Municipality, China
Showing 1–20 of 95 trials
Recruiting
Phase 3
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC600 enrolled215 locationsNCT06345729
Recruiting
Phase 1Phase 2
A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
Small Cell Lung Cancer Extensive Stage
Merck Sharp & Dohme LLC170 enrolled15 locationsNCT07227597
Recruiting
Phase 1Phase 2
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Endometrial CancerPrimary Peritoneal CarcinomaNon-small Cell Lung Cancer+6 more
Genmab764 enrolled66 locationsNCT05579366
Recruiting
Phase 1Phase 2
Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor
Lung CancerPancreas CancerThyroid Cancer+1 more
Sichuan Enray Pharmaceutical Sciences Company54 enrolled9 locationsNCT07433283
Recruiting
Not Applicable
Safety and Efficacy Evaluation of Cryoablation in the Treatment of Ground-Glass Nodules
Lung Cancer
Ruijin Hospital90 enrolled2 locationsNCT07232433
Recruiting
Phase 1
A Study of GNC-077 in Patients With Locally Advanced or Metastatic Non-small-cell Lung Cancer and Other Solid Tumors
Non-small Cell Lung CancerSolid Tumor
Sichuan Baili Pharmaceutical Co., Ltd.20 enrolled1 locationNCT06612840
Recruiting
Phase 2
Post-line Treatment With Teniposide for c-Myc-driven Extensive-stage Small Cell Lung Cancer
Lung NeoplasmsThoracic NeoplasmsLung Diseases+1 more
Shanghai Pulmonary Hospital, Shanghai, China15 enrolled1 locationNCT06758700
Recruiting
Phase 2
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer
Extensive-stage Small-cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd.66 enrolled1 locationNCT06437509
Recruiting
Phase 1Phase 2
A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC
Non-small Cell Lung Cancer (NSCLC)
Suzhou Suncadia Biopharmaceuticals Co., Ltd.400 enrolled1 locationNCT06754930
Recruiting
Phase 1Phase 2
Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
Non-small Cell Lung CancerKRAS P.G12C
Allist Pharmaceuticals, Inc.240 enrolled27 locationsNCT05288205
Recruiting
Not Applicable
GT201 Injection in Combination with Teraplizumab Injection for Treatment of Patients with Non-small Cell Lung Cancer
Non-small Cell Lung CancerAdult
Grit Biotechnology20 enrolled3 locationsNCT06235242
Recruiting
Phase 2
Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and Carboplatin
Lung Cancer, Small Cell
Shanghai Chest Hospital52 enrolled1 locationNCT06698965
Recruiting
Phase 3
ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer
Small Cell Lung Cancer
Hansoh BioMedical R&D Company460 enrolled9 locationsNCT06498479
Recruiting
Not Applicable
AI-Assisted Non-Contrast CT for Multi-Cancer Screening
Breast CancerLung CancersLiver Cancer+4 more
Guo ShiWei1,000,000 enrolled1 locationNCT06632886
Recruiting
Primary Tumor Resection for M1a Stage Lung Cancer
Lung Cancer MetastaticSurgical Resection
Fudan University66 enrolled1 locationNCT06547710
Recruiting
Phase 1
A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors
Non-small Cell Lung Cancer
Qilu Pharmaceutical Co., Ltd.250 enrolled5 locationsNCT06403735
Recruiting
Phase 1
SNC115 Injections in Patients With Recurrent/Refractory Small Cell Lung Cancer and Lung Large Cell Neuroendocrine Carcinoma
Recurrent/Refractory Small Cell Lung Cancer Lung Large Cell Neuroendocrine Carcinoma
Shanghai Simnova Biotechnology Co.,Ltd.35 enrolled1 locationNCT06384482
Recruiting
Neuroendocrine Transformation in RB1/TP53 Inactivated NSCLC
Non-small Cell Lung CancerNeuroendocrine CarcinomaHistology Transformation
Fudan University50 enrolled1 locationNCT06369181
Recruiting
Phase 3
SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations
Non-small Cell Lung Cancer
Nanjing Sanhome Pharmaceutical, Co., Ltd.242 enrolled1 locationNCT06080776
Recruiting
Phase 2
Efficiency and Safety of Microwave Ablation Plus Immune Checkpoint Inhibitor for Patients With Multiple Primary Lung Cancer: A Open, Multi-center, Phase II Clinical Trial
Multiple Primary Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China146 enrolled6 locationsNCT05053802